Deploying AI Within Medical Affairs to Improve Data Analysis & Strategy Implementation

STUDY OVERVIEW
BENCHMARK CLASS
SPECIAL OFFER

Non-members: Click here to review a complimentary excerpt from “Benchmarking Real-World Uses of Artificial Intelligence in Medical Affairs: AI for Data Analysis and Strategy”

STUDY OVERVIEW

The Medical Affairs function is uniquely poised to leverage machine learning and artificial intelligence (AI) technologies to enhance its strategic value and maximize impact. To remain competitive, Medical Affairs leaders must identify how best to utilize AI to improve data analysis and enhance their strategy for the highest near-term impact.

Best Practices, LLC undertook research to benchmark the use of artificial intelligence for data analysis and strategy implementation. This study investigates how leading biopharma organizations are applying artificial intelligence within Medical Affairs to improve data analysis and evidence generation, modify medical strategy, and enhance medical operations.

KEY TOPICS

Use of Artificial Intelligence to Improve Data Analysis and Evidence Generation
Use of Artificial Intelligence to Enhance Medical Strategy
Use of Artificial Intelligence to Refine Medical Operations

KEY METRICS

Have your Medical Affairs organizations experimented with any of the listed AI applications relating to big data analysis or evidence generation?
How valuable are each of the AI applications leveraged for the purposes of big data analysis and evidence generation?
Of the AI applications experimented with for big data analysis and evidence generation, which provide the best insights?
Have your Medical Affairs organizations experimented with any of the listed AI applications relating to strategy and operations?
How valuable are each of the AI applications leveraged for the purposes of medical strategy and operations?
Of the AI applications experimented with for medical strategy and operations, which provide the best insights?

SAMPLE KEY FINDINGS

Medical Strategy: Up to 45% of organizations use AI for competitive intelligence insights, literature review, identification of new patient groups, and clinical trial insights (selection/design/recruitment).

METHODOLOGY

Best Practices, LLC engaged 29 Medical leaders from 22 pharma companies in this research through a benchmarking survey instrument.

Industries Profiled:
Biopharmaceutical; Medical Device; Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Health Care; Consulting; Communications; Clinical Research; Laboratories

Companies Profiled:
Apellis Pharmaceuticals; ASC Therapeutics; Baxter International; Bayer; Boehringer Ingelheim; Cormedix Inc.; Curis; Daiichi Sankyo; Eisai; EMD Serono; Indivior; Ipsen; Luzsana Biotechnology; Medexus Pharmaceuticals; MEDiSTRAVA; MedThink SciCom; Merck; Novartis; Sanofi; Straumann; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.

Benchmarking Real-World Uses of Artificial Intelligence in Medical Affairs: AI for Data Analysis and Strategy

ID: 5746

Features:

Pages/Slides: 27

Published: 2022

Delivery Format: Online PDF Document

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
62163E21253BFE703002589210039CACE
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-benchmarking-real-world-uses-of-artificial-intelligence-in-medical-affairs-ai-for-data-analysis-strategy?opendocument
18
19opendocument
2044.200.168.16
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB